Amicus Therapeutics (FOLD) Lifted to Strong-Buy at ValuEngine

ValuEngine upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a buy rating to a strong-buy rating in a report issued on Friday morning.

FOLD has been the subject of several other research reports. Zacks Investment Research upgraded shares of Amicus Therapeutics from a sell rating to a hold rating in a research note on Thursday, May 10th. BidaskClub downgraded shares of Amicus Therapeutics from a strong-buy rating to a buy rating in a research note on Friday, June 1st. Finally, Cowen restated a buy rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research note on Tuesday, May 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $19.93.

NASDAQ:FOLD opened at $14.31 on Friday. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30. Amicus Therapeutics has a 52 week low of $12.04 and a 52 week high of $17.62.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.33). The business had revenue of $21.31 million during the quarter, compared to the consensus estimate of $18.92 million. Amicus Therapeutics had a negative net margin of 460.04% and a negative return on equity of 53.45%. equities analysts anticipate that Amicus Therapeutics will post -1.23 EPS for the current year.

In related news, CFO William D. Baird III sold 10,000 shares of the business’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $15.63, for a total transaction of $156,300.00. Following the completion of the transaction, the chief financial officer now owns 117,622 shares in the company, valued at $1,838,431.86. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Hung Do sold 25,000 shares of the business’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the transaction, the insider now owns 421,771 shares of the company’s stock, valued at approximately $6,326,565. The disclosure for this sale can be found here. In the last quarter, insiders have sold 75,000 shares of company stock valued at $1,187,450. Insiders own 2.90% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of Amicus Therapeutics by 6.1% during the second quarter. BlackRock Inc. now owns 16,017,301 shares of the biopharmaceutical company’s stock worth $250,190,000 after purchasing an additional 927,049 shares in the last quarter. Redmile Group LLC grew its stake in shares of Amicus Therapeutics by 7.1% during the first quarter. Redmile Group LLC now owns 10,738,658 shares of the biopharmaceutical company’s stock worth $161,509,000 after purchasing an additional 712,888 shares in the last quarter. Palo Alto Investors LP grew its stake in shares of Amicus Therapeutics by 2.4% during the first quarter. Palo Alto Investors LP now owns 6,147,829 shares of the biopharmaceutical company’s stock worth $92,463,000 after purchasing an additional 141,807 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Amicus Therapeutics by 1.3% during the first quarter. Franklin Resources Inc. now owns 3,767,389 shares of the biopharmaceutical company’s stock worth $56,661,000 after purchasing an additional 48,490 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of Amicus Therapeutics by 18.0% during the second quarter. Victory Capital Management Inc. now owns 3,606,039 shares of the biopharmaceutical company’s stock worth $56,325,000 after purchasing an additional 550,740 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Read More: What is the NASDAQ?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply